BCMA-directed CAR T-cell therapy may be effective against high-risk smoldering myeloma, according to results from the phase II CAR-PRISM trial reported by
@OmarNadeemMD
at #AACR26.
https://
brnw.ch/21x1Ljj
@danafarber

@harvardmed